Cano C, Malik K U
Department of Pharmacology, School of Medicine, University of Tennessee, Memphis.
J Pharmacol Exp Ther. 1992 May;261(2):660-8.
The subtype of adenosine receptor linked to cardiac prostacyclin (PGI2) synthesis, measured as immunoreactive 6-keto-PGF1 alpha, was investigated in the rabbit heart perfused with Krebs' buffer at 20 ml/min. Adenosine (6.4-50 nmol) decreased 6-keto-PGF1 alpha synthesis, coronary perfusion pressure (PP) and myocardial contractility (dp/dt max), whereas higher doses (200 nmol) increased 6-keto-PGF1 alpha output and decreased PP, heart rate (HR) and dp/dt max. Injections (3.2-50 nmol) or infusion (0.6 microM) of A1 receptor agonist 1-deaza,2-chloro,N6 cyclopentyladenosine increased 6-keto-PGF1 alpha production and decreased HR and PP without affecting dp/dt max. 1-Deaza,2-chloro,N6 cyclopentyladenosine 100 to 200 nmol produced similar effects as lower doses except that it decreased transiently PP and reduced dp/dt max. 1,3-Dipropyl,8-cyclopentylxanthine (0.06 microM) prevented the effects of 1-deaza,2-chloro,N6 cyclopentyladenosine (50 mumol) and adenosine (10 microM) to increase 6-keto-PGF1 alpha output and decrease HR and minimized the decrease in dp/dt max. A2 receptor agonist 2-[p-(2-carboxyethyl)-phenethylamino]-5'-N-ethylcarboxamido-ade nos ine (1.6-12.5 nmol) or 0.6 microM decreased 6-keto-PGF1 alpha output, PP and dp/dt max without changes in HR. 3,7-Dimethyl-1-propargylxanthine prevented 2-[p-(2-carboxyethyl)-phenethylamino]-5'-N-ethylcarboxamido adenosine-induced decrease in 6-keto-PGF1 alpha output, PP and dp/dt max; HR was not altered by this agent. These data suggest that stimulation of A2 receptors reduce cardiac PGI2 synthesis and PP, but activation of A1 adenosine receptors increased PGI2 synthesis, produced vasoconstriction and decreased HR.(ABSTRACT TRUNCATED AT 250 WORDS)
以免疫反应性6-酮-前列环素F1α(6-keto-PGF1α)来衡量,研究了与心脏前列环素(PGI2)合成相关的腺苷受体亚型,实验采用流速为20毫升/分钟的Krebs缓冲液灌注兔心脏。腺苷(6.4 - 50纳摩尔)可降低6-酮-前列环素F1α的合成、冠状动脉灌注压(PP)和心肌收缩力(dp/dt max),而更高剂量(200纳摩尔)则增加6-酮-前列环素F1α的输出,并降低PP、心率(HR)和dp/dt max。注射(3.2 - 50纳摩尔)或输注(0.6微摩尔)A1受体激动剂1-脱氮-2-氯-N6-环戊基腺苷可增加6-酮-前列环素F1α的生成,并降低HR和PP,但不影响dp/dt max。100至200纳摩尔的1-脱氮-2-氯-N6-环戊基腺苷产生的效应与较低剂量相似,只是它会使PP短暂降低并使dp/dt max减小。1,3-二丙基-8-环戊基黄嘌呤(0.06微摩尔)可阻止1-脱氮-2-氯-N6-环戊基腺苷(50微摩尔)和腺苷(10微摩尔)增加6-酮-前列环素F1α输出及降低HR的效应,并使dp/dt max的降低最小化。A2受体激动剂2-[对-(2-羧乙基)-苯乙氨基]-5'-N-乙基甲酰胺基腺苷(1.6 - 12.5纳摩尔)或0.6微摩尔可降低6-酮-前列环素F1α的输出、PP和dp/dt max,而HR无变化。3,7-二甲基-1-丙炔基黄嘌呤可阻止2-[对-(2-羧乙基)-苯乙氨基]-5'-N-乙基甲酰胺基腺苷诱导的6-酮-前列环素F1α输出、PP和dp/dt max的降低;该药物对HR无影响。这些数据表明,刺激A2受体可降低心脏PGI2的合成和PP,但激活A1腺苷受体可增加PGI2的合成,产生血管收缩并降低HR。(摘要截短至250字)